试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-13
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
编号:NCT02908451登记状态:提前终止企业 / 申办者:AbGenomics B.V Taiwan Branch
药物 / 成分:AbGn-107
登记的停止原因(原文):COVID-19 pandemic has caused a huge operational difficulty for this ongoing clinical trial, as many hospitals have set limitations on onsite staff, patient visits, study related procedures and onsite monitoring visits.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-13
Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery
编号:NCT03200600登记状态:提前终止企业 / 申办者:Peking University First Hospital
药物 / 成分:Dexamethasone、Normal saline、Flurbiprofen axetil、Lipid microsphere
登记的停止原因(原文):Protocol violation occurred frequently during the postoperative period.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-13
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
编号:NCT03703791登记状态:提前终止企业 / 申办者:Aimmune Therapeutics, Inc.
药物 / 成分:AR101
登记的停止原因(原文):Sponsor terminated study; no impact on overall benefit risk evaluation of AR101
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-13
Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
编号:NCT03784963登记状态:提前终止企业 / 申办者:University of Chicago
药物 / 成分:Omega 3 fatty acids、Placebo
登记的停止原因(原文):Low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-12
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
编号:NCT01009281登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:AIN457
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-12
Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
编号:NCT03126760登记状态:提前终止企业 / 申办者:Mallinckrodt ARD LLC
药物 / 成分:Acthar Gel、Placebo
登记的停止原因(原文):Recruitment difficulties and COVID-19 logistical challenges; no safety concerns
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-09
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
编号:NCT00001962登记状态:提前终止企业 / 申办者:National Heart, Lung, and Blood Institute (NHLBI)
药物 / 成分:Daclizumab
登记的停止原因(原文):DSMB recommended closing the study and publishing the results
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-09
Predictors of AAA Expansion and/or Rupture
编号:NCT03231397登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Assess AAA rupture risk by PET-CTA scans、18F-fludeoxyglucose (FDG)、11C-PBR28
登记的停止原因(原文):We were unable to recruit more subjects who met the inclusion/exclusion criteria and we have closed the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-09
Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery
编号:NCT03682367登记状态:提前终止企业 / 申办者:University of California, Davis
药物 / 成分:Gabapentin、Placebo - Concentrate
登记的停止原因(原文):Poor Recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-09
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
编号:NCT03938337登记状态:提前终止企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Cohort 1 Not Previously Treated、Cohort 2 Treated Previously
登记的停止原因(原文):Sponsor terminated study due to higher incidence of pulmonary toxicity than expected, including death
查看官方原始记录 ↗